MedTrace Logo

Pilot Study of Neoantigen Peptides and Leukine for the Treatment of Neoplasms

NCT05475106 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2024-03-06

No results posted yet for this study

Summary

The present study is a pilot clinical trial using personalized neoantigen peptide vaccines with the addition of Leukine (Sargramostim), in patients with different types of cancer.

Conditions

  • Neoplasms

Interventions

BIOLOGICAL

Neoantigen Peptides

Patients will receive intradermal injection of individualized neoantigen peptides vaccine at a dose of \~500ug per peptide once a week for 4 weeks, and every month for 5 months after that.

Sponsors & Collaborators

  • Instituto de Medicina Regenerativa

    lead INDUSTRY

Principal Investigators

  • Jesus Perez, MD · Principal Investigator

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-12
Primary Completion
2025-11-25
Completion
2026-06-20

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05475106 on ClinicalTrials.gov